Digest Network Come funziona
Network
/
Società
Gi
Non verificato

Gilead Sciences, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieSaluteSanità

151 comunicati stampa

Guarda tutti i comunicati
30/10/2026
Eventi
Web e Social Network
Biotecnologia
Sanità
Farmaceutica
Salute
Gilead Sciences to Present at Upcoming Fourth Quarter 2026 Investor Conferences
Fonte
Gilead Sciences, Inc.
Emittente
Business Wire
1.00
0
29/10/2026
Finanza
Mercato azionario
Titoli e azioni
Web e Social Network
Telefonia e Varie
Igiene alimentare
Sanità
Medicina - Varie
Biotecnologia
HIV, AIDS e malattie autoimmuni
Salute
Farmaceutica
Oncologia
Gilead Sciences Announces Third Quarter 2026 Financial Results
Fonte
Gilead Sciences, Inc.
Emittente
Business Wire
1.00
0
22/10/2026
Salute
Sanità
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Mercato del lavoro
Industria
Gilead to Acquire Investigational Oral IL-23R Inhibitor HCXT-2001, Strengthening Its Inflammation Pipeline in IBD
Fonte
Gilead Sciences, Inc.
Emittente
Business Wire
1.00
0
22/10/2026
Salute
Sanità
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Eventi
Gilead to Present New Data on Treatment Response and Long-Term Management of Rare Liver Diseases at The Liver Meeting® 2026
Fonte
Gilead Sciences, Inc.
Emittente
Business Wire
1.00
0
19/10/2026
HIV, AIDS e malattie autoimmuni
Salute
Sanità
Medicina - Varie
Farmaceutica
Biotecnologia
Eventi
Industria
Gilead to Present New Data Across HIV and Emerging Antiviral Research at IDWeek 2026
Fonte
Gilead Sciences, Inc.
Emittente
Business Wire
1.00
0
15/10/2026
Biotecnologia
Sanità
Farmaceutica
Salute
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Gilead Sciences to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026
Fonte
Gilead Sciences, Inc.
Emittente
Business Wire
1.00
0
16/09/2026
Biotecnologia
HIV, AIDS e malattie autoimmuni
Sanità
Salute
Farmaceutica
Industria
Gilead Accelerates Global Access Planning for Investigational Once-Yearly Lenacapavir for HIV Prevention
Fonte
Gilead Sciences, Inc.
Emittente
Business Wire
1.00
0
15/09/2026
Scienza
HIV, AIDS e malattie autoimmuni
Sanità
Medicina - Varie
Biotecnologia
Farmaceutica
Salute
Mercato del lavoro
Industria
Gilead and PAHO Announce Milestone Partnership to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention Across Latin America and the Caribbean
Fonte
Gilead Sciences, Inc.
Emittente
Business Wire
1.00
0
08/09/2026
Gilead Opens State-of-the-Art Research Center to Advance the Next Generation of Medicines
Fonte
Gilead Sciences, Inc.
Emittente
Business Wire
1.00
0
27/08/2026
U.S. FDA Approves Gilead’s Bixlenvo™, a New Once-Daily Single Tablet Option for Virologically Suppressed Adults With HIV, Including Those on Complex Regimens
Fonte
Gilead Sciences, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0